[
  {
    "ts": "2025-06-19T12:03:00+00:00",
    "headline": "RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
    "summary": "RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.",
    "url": "https://finance.yahoo.com/news/rybodyn-selected-join-lilly-gateway-120300444.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "6de9be9e-b633-371f-8aa6-2d8389ab2c71",
      "content": {
        "id": "6de9be9e-b633-371f-8aa6-2d8389ab2c71",
        "contentType": "STORY",
        "title": "RyboDyn Selected to Join Lilly Gateway Labs to Advance Next-Gen Immunotherapies Targeting the Dark Proteome",
        "description": "",
        "summary": "RyboDyn, Inc., a biotechnology company pioneering first-in-class immunotherapies targeting the dark proteome, today announced its selection to join Lilly Gateway Labs (LGL) in San Diego, an innovation hub operated with Alexandria Real Estate Equities, Inc. This selection provides RyboDyn with direct access to Eli Lilly and Company's global scientific and business network—a critical catalyst as it advances its lead programs.",
        "pubDate": "2025-06-19T12:03:00Z",
        "displayTime": "2025-06-19T12:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/c2f03996730f5dc92ed1f01678e3c7ff",
          "originalWidth": 400,
          "originalHeight": 79,
          "caption": "RyboDyn logo: targeting the dark proteome (PRNewsfoto/RyboDyn)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tNAaNp6o9VnsGZP7sxaYZg--~B/aD03OTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/c2f03996730f5dc92ed1f01678e3c7ff.cf.webp",
              "width": 400,
              "height": 79,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q0_QYbaqLHJJhr.ER6y6dA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/c2f03996730f5dc92ed1f01678e3c7ff.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rybodyn-selected-join-lilly-gateway-120300444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rybodyn-selected-join-lilly-gateway-120300444.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ARE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]